Basic information
Biomarker: C22-ceramides+C16-ceramide+hydroxyhexadecenoylcarnitine+1-methyladenosine
Histology type: endometrioid endometrial carcinoma
Cohort characteristics
Country: Slovenia
Region: Maribor
Study type: prospective study
Followed up time :
Subgroup 1 number: endometrial cancer
Subgroup 2 name : no malignancie
Subgroup 1 number: 15
Subgroup 2 number: 21
Cohort statistics: Mean (SD)
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 36 | endometrial cancer | 15 | no malignancie | 21 |
Sample information
Description: C22-ceramides+C16-ceramide+hydroxyhexadecenoylcarnitine+1-methyladenosine identified as potential diagnostic biomarkers for EC
Sample type : serum
Sample method: HPLC-TQ/MS
Expression pattern : C22-ceramides+C16-ceramide+hydroxyhexadecenoylcarnitine+1-methyladenosine
Disease information
Subgroup 1 age: 64±14
Subgroup 2 age: 54±19
Related information
Expression figure legend: ROC curves and boxplot representations for 4 top performing biomarkers as analyzed by univariate analysis.
Expression figure link: https://ars.els-cdn.com/content/image/1-s2.0-S1896112620300456-gr4_lrg.jpg
